Literature DB >> 26431719

Adjunctive therapy with inhaled nitric oxide for severe acute chest syndrome in patients with sickle cell disease.

Hermann Wrigge1, Eduardo L V Costa2, Thilo Busch3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26431719     DOI： 10.1007/s00134-015-4084-7

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  11 in total

1.  Inhaled nitric oxide therapy in adults: European expert recommendations.

Authors:  Peter Germann; Antonio Braschi; Giorgio Della Rocca; Anh Tuan Dinh-Xuan; Konrad Falke; Claes Frostell; Lars E Gustafsson; Philippe Hervé; Philippe Jolliet; Udo Kaisers; Hector Litvan; Duncan J Macrae; Marco Maggiorini; Nandor Marczin; Bernd Mueller; Didier Payen; Marco Ranucci; Dietmar Schranz; Rainer Zimmermann; Roman Ullrich
Journal:  Intensive Care Med       Date:  2005-06-23       Impact factor: 17.440

2.  Pulmonary hypertension and cor pulmonale during severe acute chest syndrome in sickle cell disease.

Authors:  Armand Mekontso Dessap; Rusel Leon; Anoosha Habibi; Ruben Nzouakou; Françoise Roudot-Thoraval; Serge Adnot; Bertrand Godeau; Frederic Galacteros; Christian Brun-Buisson; Laurent Brochard; Bernard Maitre
Journal:  Am J Respir Crit Care Med       Date:  2008-01-03       Impact factor: 21.405

3.  Deaths: preliminary data for 2009.

Authors:  Kenneth D Kochanek; Jiaquan Xu; Sherry L Murphy; Arialdi M Miniño; Hsiang-Ching Kung
Journal:  Natl Vital Stat Rep       Date:  2011-03

4.  Inhaled nitric oxide for acute chest syndrome in adult sickle cell patients: a randomized controlled study.

Authors:  B Maitre; M Djibre; S Katsahian; A Habibi; K Stankovic Stojanovic; M Khellaf; I Bourgeon; F Lionnet; A Charles-Nelson; L Brochard; F Lemaire; F Galacteros; C Brun-Buisson; M Fartoukh; A Mekontso Dessap
Journal:  Intensive Care Med       Date:  2015-10-02       Impact factor: 17.440

5.  Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome.

Authors:  H Gerlach; R Rossaint; D Pappert; K J Falke
Journal:  Eur J Clin Invest       Date:  1993-08       Impact factor: 4.686

6.  Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial.

Authors:  Mark T Gladwin; Gregory J Kato; Debra Weiner; Onyinye C Onyekwere; Carlton Dampier; Lewis Hsu; R Ward Hagar; Thomas Howard; Rachelle Nuss; Maureen M Okam; Carole K Tremonti; Brian Berman; Anthony Villella; Lakshmanan Krishnamurti; Sophie Lanzkron; Oswaldo Castro; Victor R Gordeuk; Wynona A Coles; Marlene Peters-Lawrence; James Nichols; Mary K Hall; Mariana Hildesheim; William C Blackwelder; James Baldassarre; James F Casella
Journal:  JAMA       Date:  2011-03-02       Impact factor: 56.272

Review 7.  Sickle-cell disease.

Authors:  David C Rees; Thomas N Williams; Mark T Gladwin
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

8.  Inhaled nitric oxide for the adult respiratory distress syndrome.

Authors:  R Rossaint; K J Falke; F López; K Slama; U Pison; W M Zapol
Journal:  N Engl J Med       Date:  1993-02-11       Impact factor: 91.245

Review 9.  Sickle cell disease: time for a closer look at treatment options?

Authors:  Sujit Sheth; Maureen Licursi; Monica Bhatia
Journal:  Br J Haematol       Date:  2013-06-15       Impact factor: 6.998

Review 10.  Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Authors:  Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.